Develops Zorifertinib, a next-generation EGFR tyrosine kinase inhibitor designed to treat advanced non-small cell lung cancer with central nervous system metastases, achieving 100% blood-brain barrier penetration. This first-in-class therapy addresses the unmet need for effective treatments in patients with brain metastases, supported by funding from national drug innovation programs.
Funding
$23.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Advanced non-small cell lung cancer (NSCLC) often metastasizes to the central nervous system, and current treatments may not effectively penetrate the blood-brain barrier, leaving brain metastases inadequately addressed. This unmet need results in limited therapeutic options for patients with NSCLC and brain metastases.
Solution
Alpha Biopharma is developing Zorifertinib, a next-generation EGFR tyrosine kinase inhibitor (TKI) specifically designed to treat advanced NSCLC with central nervous system metastases. Zorifertinib is engineered to achieve 100% blood-brain barrier penetration, ensuring effective drug concentrations in the brain. As a first-in-class therapy, Zorifertinib addresses the critical need for treatments that can effectively target and inhibit EGFR in brain metastases, potentially improving outcomes for patients with this challenging condition. The drug has received funding from national drug innovation programs, supporting its development and clinical evaluation.
Target Audience
The primary target audience includes patients with advanced non-small cell lung cancer who have developed brain metastases, as well as oncologists and medical professionals specializing in lung cancer treatment.
Features
- Next-generation EGFR tyrosine kinase inhibitor (TKI)
- Designed specifically for advanced non-small cell lung cancer (NSCLC) with central nervous system metastases
- Achieves 100% blood-brain barrier penetration
- Unique design to avoid being a substrate for blood-brain barrier efflux transporters